NEW YORK, May 1 - Transgenomic today reported a 24 percent increase in revenue and a ballooning net loss as receding demand for its instruments contributed to a top-line shortfall.
Total revenue for the period ended March 31 came in at $9.8 million compared with $7.9 million one year ago. CEO Greg Duman said that 8 percent of its instrument sales this quarter came from commercial customers compared with between 25 and 35 percent the company usually draws.
R&D spending remained more or less unchanged at $2.7 million, Transgenomic said.
Still, net loss for the quarter ballooned to $3.4 million, or $.14 per share, compared with $1.1 million, or $.05 per share, year over year, the company said.
Transgenomic said it had roughly $35 million in cash and cash equivalents as of March 31.
Click here for more information.